TPST insider transaction filings
Tempest Therapeutics, Inc. — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-23. Screen TPST transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for TPST between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Tempest Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Angel Matthew — CEO and President, Director, 10% owner | Purchase (P): 231,482 @ $2.16 · Purchase (P): 231,482 (derivative) · Purchase (P): 231,482 (derivative) | EDGAR |
| 2026-06-17 | 4 | Yee John D. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Richey William Drake — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Maestas Nicholas — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Angel Matthew — CEO and President, Director, 10% owner | Purchase (P): 231,482 @ $2.16 | EDGAR |
| 2026-02-06 | 4 | Angel Matthew — CEO and President, Director, 10% owner | Grant/award (A): 269,621 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Simantov Ronit — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | RAAB MICHAEL — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | NICHOL GEOFFREY — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Pellizzari Christine A — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Maestas Nicholas — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Brady Stephen R — President and CEO, Director | Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Whiting Samuel — Chief Medical Officer | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Ventures IV, LLC — 10% owner Versant Venture Capital IV, L.P. — 10% owner Versant Side Fund IV, L.P. — 10% owner | Sale (S): 400,000 @ $1.35 · Sale (S): 387,999 @ $1.10 | EDGAR |
| 2024-07-08 | 4 | Brady Stephen R — President and CEO, Director | Purchase (P): 35,000 @ $2.11 | EDGAR |
| 2024-07-03 | 4 | Whiting Samuel — Chief Medical Officer | Purchase (P): 4,672 @ $2.13 | EDGAR |
| 2024-07-02 | 4 | Trojanowski Justin — Corporate Controller | Purchase (P): 7,500 @ $2.16 | EDGAR |
| 2024-06-14 | 4 | Simantov Ronit — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | RAAB MICHAEL — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | NICHOL GEOFFREY — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Pellizzari Christine A — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Brady Stephen R — President and CEO, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Whiting Samuel — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Trojanowski Justin — Principal Accounting Officer | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Maestas Nicholas — VP of Strategy and Finance | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Tempest Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-09-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-08-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-07-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TPST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →